Canigen CHPPi/LR, süstesuspensiooni pulber ja suspensioon koertele

Authorised

- Rabies virus, strain VP12, Inactivated
- Leptospira interrogans, serovar Icterohaemorrhagiae, Inactivated
- Leptospira interrogans, serovar Canicola, Inactivated
- Canine parainfluenza virus, strain Manhattan, Live
- Canine parvovirus, strain Cornell 780916, Live
- Canine adenovirus 2, strain Manhattan, Live
- Canine distemper virus, strain Lederle, Live

Product identification

Medicine name:
Canigen CHPPi/LR, süstesuspensiooni pulber ja suspensioon koertele

Active substance:
Rabies virus, strain VP12, Inactivated

Leptospira interrogans, serovar Icterohaemorrhagiae, Inactivated

Leptospira interrogans, serovar Canicola, Inactivated

Canine parainfluenza virus, strain Manhattan, Live

Canine parvovirus, strain Cornell 780916, Live

Canine adenovirus 2, strain Manhattan, Live

Canine distemper virus, strain Lederle, Live

Target species:
Dog

Route of administration:
Subcutaneous use

Product details

Active substance and strength:
Rabies virus, strain VP12, Inactivated
1.00 international unit(s) / 1.00 dose

Leptospira interrogans, serovar Icterohaemorrhagiae, Inactivated
833.00 million organisms / 1.00 dose

Leptospira interrogans, serovar Canicola, Inactivated
833.00 million organisms / 1.00 dose

Canine parainfluenza virus, strain Manhattan, Live
10000000.00 50% tissue culture infectious dose / 1.00 dose

Canine parvovirus, strain Cornell 780916, Live
10000000.00 50% tissue culture infectious dose / 1.00 dose

Canine adenovirus 2, strain Manhattan, Live
1000000.00 50% tissue culture infectious dose / 1.00 dose

Canine distemper virus, strain Lederle, Live
100000.00 50% tissue culture infectious dose / 1.00 dose

Pharmaceutical form:
Powder and suspension for suspension for injection

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QI07AJ06

Legal status of supply:
Veterinary medicinal product subject to veterinary prescription

Authorisation status:
Valid

Authorised in:

Estonia

Package description:
Available only in Estonian
Available only in Estonian

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Full application (Article 12(3) of Directive No 2001/82/EC)

Marketing authorisation holder:
Virbac

Marketing authorisation date:
15/12/2005

Manufacturing sites for batch release:
Virbac

Responsible authority:
State Agency Of Medicines

Authorisation number:
1361

Date of authorisation status change:
15/12/2005

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.